A U.S. Patent for “Methods of Shifting an Isoelectric Profile of a Protein Product and Uses Thereof” was published by  Alexion on July 14th, 2020. The present invention is Eculizumab comprising seven protein subpopulations with an isoelectric point between about 5.45 and about 6.55 produced by a method comprising: (a) fed batch culturing mammalian cells comprising a nucleic acid encoding eculizumab in a production bioreactor under conditions sufficient to produce eculizumab for a first period of time comprising a growth phase or a growth phase and a stationary phase of the mammalian cells or that comprises a growth phase of the mammalian cells… Learn More